Via Therapeutics, LLC
Doing business as Via Therapeutics LLC
- UEI
- YHRZATLXKL46
- CAGE
- 7CLS7
- Primary NAICS
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- SAM.gov registration
- Expired
Company facts
- Self-certified in SAM.gov
- Entity structure
- Partnership or Limited Liability Partnership
- NAICS codes registered in SAM.gov
- SAM.gov registration date
- Website
- viatherapeutics.com
- Founded
- 2000
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Recent federal awards
| Award | Agency | Obligated | Awarded |
|---|---|---|---|
| Dry powders of whole blood prepared by thin-film freeze-drying - blood transfusions are the most often used… | National Heart Lung and Blood Institute | $315,082 | |
| Combined amikacin and azithromycin in an inhaled formulation for the treatment of NTM - though important progresses have… | National Institute of Allergy and Infectious Diseases | $314,363 | |
| Microneedle-based mrna flu vaccine for transcutaneous immunization - flu is a contagious respiratory disease caused by… | National Institute of Allergy and Infectious Diseases | $314,363 | |
| Inhalable dry powders of mycobacteriophages for tuberculosis therapy - tuberculosis (TB) is one of the most infectious… | National Institute of Allergy and Infectious Diseases | $600,000 | |
| Sbir phase II award to via therapeutics | National Institute of Allergy and Infectious Diseases | $1,468,122 |
About Via Therapeutics, LLC
Via Therapeutics, LLC is a for-profit limited liability company based in Austin, Texas, specializing in innovative pharmaceutical research and development with a focus on advanced drug formulation technologies for infectious diseases. The company is registered in SAM.gov and has expertise in developing novel therapeutic approaches using proprietary thin-film freeze-drying technology to create advanced pharmaceutical delivery methods. Via Therapeutics focuses on creating innovative solutions for challenging medical conditions, particularly in the areas of tuberculosis, non-tuberculous mycobacterial infections, and influenza treatments.
Through federal contract awards, Via Therapeutics has secured contracts primarily from the National Institute of Allergy and Infectious Diseases (NIAID) to develop specialized pharmaceutical products. Notably, the company was awarded a $299,995 firm fixed-price contract for developing low-cost, shelf-stable clofazimine mini-tablets for treating tuberculosis in pediatric patients. The company has also received a $1.5 million contract for a Phase II small business innovation research project to develop new tuberculosis therapeutics. These contracts were set aside for small businesses and demonstrate Via Therapeutics' commitment to creating targeted, innovative medical solutions for challenging infectious disease treatments.
Via Therapeutics has been awarded multiple federal grants, also primarily from NIAID, focusing on advanced pharmaceutical research and development. These grants include a $314,363 project to develop an inhaled, fixed-dose combination powder product for treating non-tuberculous mycobacterial infections, a $314,363 grant for creating a microneedle-based mRNA flu vaccine for transcutaneous immunization, and a grant exploring inhalable dry powders of mycobacteriophages for tuberculosis therapy. Another notable grant from the National Cancer Institute supported research on epidermal/dermal targeting formulations for cutaneous squamous cell carcinoma. These grants showcase the company's innovative approach to developing advanced drug delivery systems, with a particular emphasis on creating more effective, patient-friendly treatments for infectious and challenging medical conditions.
Quick answers
What is Via Therapeutics, LLC's UEI?
Via Therapeutics, LLC's Unique Entity ID (UEI) in SAM.gov is YHRZATLXKL46.
What is Via Therapeutics, LLC's CAGE code?
Via Therapeutics, LLC's CAGE code is 7CLS7.
What is Via Therapeutics, LLC's primary NAICS code?
Via Therapeutics, LLC's primary NAICS code is 541715 (Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)).
Is Via Therapeutics, LLC registered in SAM.gov?
Via Therapeutics, LLC's SAM.gov registration expired on August 4, 2026.
What is Via Therapeutics, LLC's most recent federal award?
Via Therapeutics, LLC's most recent federal grant award is Dry powders of whole blood prepared by thin-film freeze-drying - blood transfusions are the most often used… (R41HL186958), from National Heart Lung and Blood Institute, on September 1, 2026.
On GovTribe
See Via Therapeutics, LLC's full federal record
- Federal contract awards
- Federal grant awards
- Funding analysis by agency, NAICS and set-aside
- Similar vendors